ZA955963B - Estrogen agonists as remedies for prostate diseases endometriosis and obesity - Google Patents

Estrogen agonists as remedies for prostate diseases endometriosis and obesity

Info

Publication number
ZA955963B
ZA955963B ZA955963A ZA955963A ZA955963B ZA 955963 B ZA955963 B ZA 955963B ZA 955963 A ZA955963 A ZA 955963A ZA 955963 A ZA955963 A ZA 955963A ZA 955963 B ZA955963 B ZA 955963B
Authority
ZA
South Africa
Prior art keywords
remedies
obesity
estrogen agonists
prostate diseases
endometriosis
Prior art date
Application number
ZA955963A
Other languages
English (en)
Inventor
David D Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA955963B publication Critical patent/ZA955963B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA955963A 1994-07-19 1995-07-18 Estrogen agonists as remedies for prostate diseases endometriosis and obesity ZA955963B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/276,969 US5441986A (en) 1994-07-19 1994-07-19 Estrogen agonists as remedies for prostate and cardiovascular diseases

Publications (1)

Publication Number Publication Date
ZA955963B true ZA955963B (en) 1997-01-20

Family

ID=23058874

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA955963A ZA955963B (en) 1994-07-19 1995-07-18 Estrogen agonists as remedies for prostate diseases endometriosis and obesity
ZA955964A ZA955964B (en) 1994-07-19 1995-07-18 Estrogen agonists as remedies for cardiovascular diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA955964A ZA955964B (en) 1994-07-19 1995-07-18 Estrogen agonists as remedies for cardiovascular diseases

Country Status (17)

Country Link
US (4) US5441986A (de)
EP (3) EP1029540A3 (de)
JP (2) JPH09507859A (de)
KR (2) KR100221854B1 (de)
CN (2) CN1076967C (de)
AU (2) AU694220B2 (de)
CA (2) CA2195213C (de)
FI (2) FI970215A7 (de)
HK (1) HK1000697A1 (de)
HU (2) HUT77392A (de)
IL (2) IL114585A (de)
MX (2) MX9700534A (de)
MY (1) MY113079A (de)
NZ (2) NZ285159A (de)
TW (1) TW403649B (de)
WO (2) WO1996002242A1 (de)
ZA (2) ZA955963B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US5726207A (en) * 1996-02-28 1998-03-10 Pfizer Inc. Protection of ischemic myocardium against reperfusion damage
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
FI982733L (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
CN1250563C (zh) 1999-05-04 2006-04-12 斯特拉坎有限公司 雄激素糖苷及其产生雄性征的活性
CA2376158C (en) * 1999-07-06 2011-03-15 Endorecherche, Inc. Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
MX2008014825A (es) * 2006-05-22 2008-12-01 Hormos Medical Ltd Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana.
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
PL2121553T3 (pl) * 2007-02-14 2012-11-30 Hormos Medical Ltd Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
FR2619383B1 (fr) * 1987-08-12 1989-12-08 Inst Vaisseaux Sang Proteine a activite vasculaire, derivee des monocytes et ses analogues, procede pour son extraction et leurs utilisations en therapeutique et pour la preparation d'anticorps
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4401554A1 (de) * 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases

Also Published As

Publication number Publication date
JPH09507860A (ja) 1997-08-12
IL114586A0 (en) 1995-11-27
KR100221854B1 (ko) 1999-09-15
TW403649B (en) 2000-09-01
EP0769941A1 (de) 1997-05-02
US5441986A (en) 1995-08-15
CA2195093C (en) 2000-03-07
HUT77392A (hu) 1998-04-28
JPH09507859A (ja) 1997-08-12
NZ285158A (en) 2000-07-28
AU2416995A (en) 1996-02-16
IL114586A (en) 2000-06-29
US5827892A (en) 1998-10-27
ZA955964B (en) 1997-01-20
IL114585A0 (en) 1995-11-27
NZ285159A (en) 2000-10-27
CA2195213C (en) 2000-03-14
CN1076967C (zh) 2002-01-02
IL114585A (en) 2000-01-31
KR970704430A (ko) 1997-09-06
CN1152868A (zh) 1997-06-25
FI970214A0 (fi) 1997-01-17
HU9700163D0 (en) 1997-03-28
EP1029540A2 (de) 2000-08-23
JP2930424B2 (ja) 1999-08-03
FI970215A0 (fi) 1997-01-17
MX9700534A (es) 1997-04-30
FI970214A7 (fi) 1997-01-17
EP1029540A3 (de) 2001-05-16
HU9700162D0 (en) 1997-03-28
FI970214L (fi) 1997-01-17
EP0771194A1 (de) 1997-05-07
US5902830A (en) 1999-05-11
CA2195213A1 (en) 1996-02-01
WO1996002242A1 (en) 1996-02-01
AU689257B2 (en) 1998-03-26
MY113079A (en) 2001-11-30
WO1996002243A1 (en) 1996-02-01
HK1000697A1 (en) 2002-05-10
FI970215L (fi) 1997-01-17
HUT77391A (hu) 1998-04-28
KR100212352B1 (ko) 1999-08-02
AU2417095A (en) 1996-02-16
US5852059A (en) 1998-12-22
MX9700538A (es) 1997-04-30
FI970215A7 (fi) 1997-01-17
KR970704429A (ko) 1997-09-06
CA2195093A1 (en) 1996-02-01
AU694220B2 (en) 1998-07-16
CN1153473A (zh) 1997-07-02

Similar Documents

Publication Publication Date Title
IL114585A0 (en) Estrogen agonists as remedies for prostate diseases endometriosis and obesity
GB2360519B (en) Appetite suppressant steroidal glycosides
HUP0200740A3 (en) Estrogen receptor-betha ligands and their use
PL348113A1 (en) Drug delivery device, especially for the delivery of progestins and estrogens
IL137223A (en) Hose fitting and die for preparation
GB2292976B (en) Device for fastening turbochargers
EP0889051A4 (de) Triterpen-derivate und heilmittel fur lebererkrankungen
IL129194A (en) Hormonal composition consisting of an estrogen compound and of a progestational compound
EP0767177A4 (de) Triterpenderivat und medizinische zusammensetzungen
AP2002002475A0 (en) Hormonal composition based on a progesterone and an oestrogen and use thereof
NZ294508A (en) Androstane derivatives
AU7342298A (en) Induction heating device for metal pieces
AU3622395A (en) Snorguard anti snoring device
IL120265A0 (en) Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
EP0713726A3 (de) Spänezerkleinerer
IL120488A (en) Modifiers for water-setting inorganic compositions and modified water-setting inorganic compositions
ZA971718B (en) Combination therapy to prevent bone loss-progesterone and estrogen agonists
HUP9901474A3 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
EP0917878A4 (de) Arzneimittel gegen hepatitis
IL132131A0 (en) Prophylactics and remedies for renal diseases
HUP9902650A3 (en) Butadiene derivatives and process for preparing thereof
PL328860A1 (en) Ensilage facilitating agent
AU8934898A (en) Use of droloxifene for the treatment of prostatic diseases endometriosis and obesity
GB2300811B (en) Contraceptive device
AU2003206424A1 (en) Sequential estrogen/progesterone antagonist combination for hormone replacement therapy